Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros

Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Oncogene ; 26(33): 4749-60, 2007 Jul 19.
Artículo en Inglés | MEDLINE | ID: mdl-17297441

RESUMEN

The mechanisms underlying cellular drug resistance have been extensively studied, but little is known about its regulation. We have previously reported that activating transcription factor 4 (ATF4) is upregulated in cisplatin-resistant cells and plays a role in cisplatin resistance. Here, we find out a novel relationship between the circadian transcription factor Clock and drug resistance. Clock drives the periodical expression of many genes that regulate hormone release, cell division, sleep-awake cycle and tumor growth. We demonstrate that ATF4 is a direct target of Clock, and that Clock is overexpressed in cisplatin-resistant cells. Furthermore, Clock expression significantly correlates with cisplatin sensitivity, and that the downregulation of either Clock or ATF4 confers sensitivity of A549 cells to cisplatin and etoposide. Notably, ATF4-overexpressing cells show multidrug resistance and marked elevation of intracellular glutathione. The microarray study reveals that genes for glutathione metabolism are generally downregulated by the knockdown of ATF4 expression. These results suggest that the Clock and ATF4 transcription system might play an important role in multidrug resistance through glutathione-dependent redox system, and also indicate that physiological potentials of Clock-controlled redox system might be important to better understand the oxidative stress-associated disorders including cancer and systemic chronotherapy.


Asunto(s)
Factor de Transcripción Activador 4/genética , Resistencia a Antineoplásicos/genética , Transactivadores/genética , Transcripción Genética , Factor de Transcripción Activador 4/metabolismo , Antineoplásicos/farmacología , Northern Blotting , Western Blotting , Proteínas CLOCK , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Inmunoprecipitación de Cromatina , Cisplatino/farmacología , Etopósido/farmacología , Perfilación de la Expresión Génica , Regulación Neoplásica de la Expresión Génica , Glutatión/metabolismo , Humanos , Neoplasias/genética , Neoplasias/metabolismo , Neoplasias/patología , Oxidación-Reducción , Interferencia de ARN , Transactivadores/metabolismo
2.
Br J Pharmacol ; 131(8): 1513-20, 2000 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-11139426

RESUMEN

BAY 12-9566 (4-[4-(chlorophenyl)phenyl]-4-oxo-2S-(phenylthiomethyl) butanoic acid) is a newly developed, synthetic matrix metalloproteinase (MMP) inhibitor (MMPI) that selectively inhibits MMP-2, MMP-3 and MMP-9 isozymes. We study the effect of BAY 12-9566 on inflammation and cartilage destruction in adjuvant-induced arthritis (AA) in rats. Rats were injected with adjuvant and treated for 21 days with vehicle, Indomethacin or BAY 12-9566. AA was assessed: by measuring arthritic index, paw volume, urinary pyridinoline (Pyr) and deoxypyridinoline (Dpyr); by examining joint inflammation; and by microscopic morphometry of articular cartilages. Oral treatment of rats for 22 days with 50 mg kg(-1) body weight/d BAY 12-9566 showed decreased AA as determined by improvement in body weight gain (P<0.01), arthritic index (P<0.05) and swelling of paws contralateral to the adjuvant injection site (P<0.05). Neutrophil infiltration and collagen degradation were also significantly lower (P<0.01) in this treatment group. Cartilage destruction was successfully suppressed (P<0.01) in rats treated with either 50 mg kg(-1) body weight/d BAY 12-9566 or 1 mg kg(-1) body weight/d Indomethacin. These results indicate that BAY 12-9566 successfully suppressed inflammation and cartilage destruction in rats with AA. Moreover, these results also suggested that MMP-2, MMP-3 and MMP-9 are involved in arthritic diseases such as rheumatoid arthritis.


Asunto(s)
Antineoplásicos/farmacología , Artritis Experimental/prevención & control , Inhibidores de la Metaloproteinasa de la Matriz , Compuestos Orgánicos , Aminoácidos/efectos de los fármacos , Aminoácidos/orina , Animales , Artritis Experimental/enzimología , Artritis Experimental/patología , Compuestos de Bifenilo , Peso Corporal/efectos de los fármacos , Edema/patología , Edema/prevención & control , Miembro Posterior , Indometacina/farmacología , Inflamación/prevención & control , Masculino , Fenilbutiratos , Ratas , Ratas Sprague-Dawley , Aumento de Peso/efectos de los fármacos
3.
Gene ; 75(2): 197-211, 1989 Feb 20.
Artículo en Inglés | MEDLINE | ID: mdl-2714651

RESUMEN

Sequences totalling 5472 nucleotides (nt) from four complementary DNA (cDNA) clones of the dengue virus type 2 (DEN-2) RNA (New Guinea strain, NGS-C) have been reported previously [Yaegashi et al., Gene 46 (1986) 257-267; Putnak et al., Virology 163 (1988) 93-103]. This report describes the complete nucleotide sequence, with the exception of about 7 nt at the 5'-noncoding region, of this RNA genome derived from several cDNA clones. It is 10,723 nt in length and contains a single long open reading frame of 10,173 nt, encoding a polyprotein of 3391 amino acids. The genomic organization is similar to that of other flaviviruses that have recently been reported. Among the three DEN-2 strains - the Jamaica genotype (DEN-2JAM), the DEN-2NGS-C, and the S1 candidate vaccine strain derived from Puerto Rico (PR)-159 isolate (DEN-2S1) - which have been sequenced to date, the amino acid sequences of the polyproteins bear 94%-99% similarity. When the amino acid sequences of DEN-2NGS-C are compared with those of the other two strains, the variations are greater in the DEN-2S1 than in the DEN-2JAM. When DEN-2 and DEN-4 are compared, the overall amino acid identities range from 30% to 80% in both the structural and nonstructural proteins; whereas between DEN-2 and DEN-1, they range from 68% to 79% in the region encoding the structural proteins and the nonstructural protein NS1.


Asunto(s)
Virus del Dengue/genética , Genes Virales , Variación Genética , Proteínas Virales/genética , Secuencia de Aminoácidos , Secuencia de Bases , Evolución Biológica , Clonación Molecular , Cisteína/genética , ADN , Virus del Dengue/inmunología , Glicosilación , Datos de Secuencia Molecular , Nueva Guinea , Procesamiento Proteico-Postraduccional , ARN Viral/genética , Serotipificación , Especificidad de la Especie
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA